Chung YL - Search Results

1

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Al-Saffar NM, et al. Among authors: chung yl. Cancer Res. 2006 Jan 1;66(1):427-34. doi: 10.1158/0008-5472.CAN-05-1338. Cancer Res. 2006. PMID: 16397258

2

Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway.

Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL, Stubbs M. Griffiths JR, et al. Among authors: chung yl. Cancer Res. 2002 Feb 1;62(3):688-95. Cancer Res. 2002. PMID: 11830521

3

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.

Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Chung YL, et al. J Natl Cancer Inst. 2003 Nov 5;95(21):1624-33. doi: 10.1093/jnci/djg084. J Natl Cancer Inst. 2003. PMID: 14600095

4

Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.

Chung YL, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR. Chung YL, et al. Clin Cancer Res. 2004 Jun 1;10(11):3863-70. doi: 10.1158/1078-0432.CCR-03-0237. Clin Cancer Res. 2004. PMID: 15173095

5

Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.

McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP. McPhail LD, et al. Among authors: chung yl. Clin Cancer Res. 2005 May 15;11(10):3705-13. doi: 10.1158/1078-0432.CCR-04-2504. Clin Cancer Res. 2005. PMID: 15897567

6

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Chung YL, et al. Neoplasia. 2008 Apr;10(4):303-13. doi: 10.1593/neo.07834. Neoplasia. 2008. PMID: 18392140 Free PMC article.

7

Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.

Beloueche-Babari M, Arunan V, Troy H, te Poele RH, te Fong AC, Jackson LE, Payne GS, Griffiths JR, Judson IR, Workman P, Leach MO, Chung YL. Beloueche-Babari M, et al. Among authors: chung yl. Cancer Res. 2012 Feb 15;72(4):990-1000. doi: 10.1158/0008-5472.CAN-11-2688. Epub 2011 Dec 22. Cancer Res. 2012. PMID: 22194463 Free PMC article.

8

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, Chung YL, Eykyn TR, Smith PD, Leach MO. Beloueche-Babari M, et al. Among authors: chung yl. Cancer Res. 2017 Nov 1;77(21):5913-5924. doi: 10.1158/0008-5472.CAN-16-2686. Epub 2017 Sep 18. Cancer Res. 2017. PMID: 28923861 Free PMC article.

9

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL. Al-Saffar NMS, et al. Among authors: chung yl. Br J Cancer. 2018 Oct;119(9):1118-1128. doi: 10.1038/s41416-018-0242-3. Epub 2018 Oct 31. Br J Cancer. 2018. PMID: 30377337 Free PMC article.

10

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J; Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee. Workman P, et al. Among authors: chung yl. J Natl Cancer Inst. 2006 May 3;98(9):580-98. doi: 10.1093/jnci/djj162. J Natl Cancer Inst. 2006. PMID: 16670384 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters